Giant Cell Arteritis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of giant cell arteritis (GCA) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report both the incidence and prevalence of GCA for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report.
Clarivate Epidemiology’s GCA forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of GCA over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of diagnosed incident cases for each forecast year, Clarivate Epidemiology provides 20 years of forecast data for the following GCA subpopulations:
- Diagnosed prevalent cases.
- Diagnosed incident cases with PMR.
Note: Coverage may vary by country.
Table of contents
- Giant Cell Arteritis - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Key Updates
- Diagnosed Incidence of Giant Cell Arteritis per 100,000 per Year Among People Aged 50+ in 2022 and 2042
- Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Giant Cell Arteritis Over the Next 20 Years
- Analysis of the Diagnosed Incident Cases of Giant Cell Arteritis in 2022 by Comorbidity
- Key Findings
- Epidemiology Data
- Methods
- Diagnosed Prevalent Cases
- Diagnosed Incident Cases
- Diagnosed Incident Cases by Polymyalgia Rheumatica Status
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Giant Cell Arteritis
- Studies Excluded From the Analysis of Giant Cell Arteritis
- Risk / Protective Factors
- Risk / Protective Factors for Giant Cell Arteritis
- Bibliography
- Abbreviations
- Glossary
- Literature Review
- Introduction
Stephanie Niquita Phankon, M.B.B.S., M.P.H., Manager, Epidemiology. Ms. Phankon’s expertise is in autoimmune and inflammatory diseases and hematological malignancies. She holds a master’s in public health specializing in epidemiology from TISS in Mumbai and a medical degree from Hubei University of Chinese Medicine in the People’s Republic of China. She has been trained as a community physician and has supervised and coordinated various governmental and nongovernmental public health projects.
Mudasir Khan, M.P.H., Manager, Epidemiology. Before joining Clarivate, Mr. Khan worked as a team lead at IKS Health, an organization that works on patient-level healthcare data management. His areas of expertise at the Clarivate epi team are oncology and psychiatry. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.